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Abstract
Background: Mycobacterium abscessus complex (MABC) is the most drug resistant of the mycobacterial pathogens.
M. abscessus subsp. abscessus encodes a functional erythromycin ribosomal methylase gene, erm(41), causing inducible
macrolide resistance. However, some clinical isolates of M. abscessus subsp. abscessus harboring nonfunctional erm(41)
were susceptible to macrolide, even after extended incubation of 14 days. Loss of function of the erm(41) genes was
associated with a T-to-C substitution at position 28 of the gene (T28C), leading to an amino acid change from Trp to
Arg at codon 10. Pulmonary disease caused by M. abscessus subsp. abscessus strains with an nonfunctional erm(41)
(C28 sequevar) may be responsive to macrolide-containing antibiotic regimens. Therefore, all M. abscessus subsp.
abscessus strains with a functional erm(41) (T28 sequevar) were thought to be resistant to macrolide with extended
incubation. Here, we report the first case of pulmonary disease caused by a strain of M. abscessus subsp. abscessus
which was susceptible to macrolide due to T19 sequevar of erm(41) gene.
Case presentation: A 62-year-old Korean female was referred to our hospital due to chronic cough, sputum,
and hemoptysis lasting more than 5 months. The patient’s sputum was positive for acid-fast bacilli staining and
nontuberculous mycobacteria (NTM) were isolated twice from sputum specimens. The isolate was identified as
M. abscessus subsp. abscessus. The isolate had a point mutation of C→ T at position 19 (C19→ T) in the erm(41)
gene, instead of expected C28 sequevar of erm(41), and had no rrl mutation. The isolate displayed a clarithromycin
susceptible phenotype with an Arg→ Stop codon change in erm(41). The patient was successfully treated with a
macrolide-containing regimen.
Conclusion: This is the first case of pulmonary disease caused by a strain of M. abscessus subsp. abscessus showing
clarithromycin susceptible phenotype due to T19 sequevar of the erm(41) gene. The erm(41) gene is clinically important,
and non-functional erm alleles may be an important issue for the management of MABC lung disease. The presence of
a non-functional erm(41) allele in M. abscessus subsp. abscessus isolates may be associated with better outcomes.
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Background
The prevalence of lung diseases caused by nontuberculous
mycobacteria (NTM) is increasing worldwide [1, 2]. Myco-
bacterium abscessus complex (MABC) is a rapidly grow-
ing mycobacterium and is the second most common
cause of NTM lung disease after M. avium complex in
many countries [3–5]. In addition, MABC has emerged as
an important pathogen in patients with cystic fibrosis and
chronic lung diseases, such as bronchiectasis [6–10].
MABC is the most drug resistant of mycobacterial
pathogens, resulting in limited therapeutic options and a
high treatment failure rate [11–14]. MABC is comprised
of three closely related subspecies: M. abscessus subsp.
abscessus, M. abscessus subsp. massiliense and M.
abscessus subsp. bolletii [15, 16]. M. abscessus subsp.
abscessus encodes a functional erythromycin ribosomal
methylase gene, erm(41), which modifies the binding site
for macrolide antibiotics, causing inducible macrolide
resistance [17–19]. However, some clinical isolates of M.
abscessus subsp. abscessus were susceptible to macrolide
antibiotics, even after extended incubation of 14 days [20].
Loss of function of erm(41) genes was associated with a T-
to-C substitution at position 28 of the gene (T28C), lead-
ing to an amino acid change from Trp to Arg at codon 10
[17, 18]. Pulmonary disease caused by these strains with
M. abscessus subsp. abscessus with C28 sequevar may be
responsive to macrolide-containing antibiotic regimens
[20]. Conversely, all M. abscessus subsp. abscessus strains
with a T28 sequevar were thought to be resistant to clari-
thromycin with extended incubation [18].
Although there were multiple polymorphisms asso-
ciated with amino acid changes, only this T28C substi-
tution resulted in loss of erm(41) gene function and
no other nucleotide substitution was known to be
associated with macrolide susceptibility [20]. We re-
port the first case of pulmonary disease caused by a
strain of M. abscessus subsp. abscessus that was sus-
ceptible to clarithromycin due to a T19 sequevar of
the erm(41) gene. The patient was treated successfully
with macrolide-containing antibiotics. This study was
approved by the institutional review board of the Sam-
sung Medical Center.
Case presentation
A 62-year-old Korean female was referred to our hos-
pital due to chronic cough, sputum, and hemoptysis last-
ing more than 5 months. She was a non-smoker and had
no history of previous treatment for pulmonary tubercu-
losis. The patient was 149.7 cm tall and weighed 40.7 kg.
The erythrocyte sedimentation rate was 77 mm/h, and
C-reactive protein was 2.37 mg/dL. A human immuno-
deficiency virus antibody test was negative. A chest com-
puted tomography (CT) scan revealed bronchiectasis
and bronchiolitis in both lungs, suggesting the nodular
bronchiectatic form of NTM lung disease (Fig. 1a).
The patient’s sputum was positive for acid-fast bacilli
staining and NTM were isolated twice from sputum
specimens in both solid (3 % Ogawa solid media;
Shinyang, Seoul, South Korea) and liquid culture system
(Bactec MGIT 960 system; BD Diagnostics, Sparks, MD,
USA). To identify an etiological agent, bacteria grown in
the MGIT 960 culture system were initially propagated
in 7H9 broth (Difco Laboratories, Detroit, MI, USA)
supplemented with 10 % (vol/vol) oleic acid-albumin-
dextrose-catalase (OADC; BD Diagnostics) for 7 days at
37 °C. They were then sub-cultured in egg-based 3 %
Ogawa solid media (Shinyang, Seoul, South Korea), and
genomic DNA was extracted from cultured bacteria. M.
abscessus was the initial species identified using a reverse
line blot hybridization assay (REBA Myco-ID; M&D,
Inc., Wonju, South Korea) based on the rpoB gene [21].
To confirm the accuracy of this identification, sequencing
analyses of rpoB, hsp65, and 16S rRNA were performed
using GenBank (http://blast.ncbi.nlm.nih.gov/) with the
BLAST algorithm [22–24]. The 16S rRNA sequences were
100 % identical to M. abscessus subsp. abscessus (GenBank
accession no. NR074427), M. abscessus subsp. massiliense
(GenBank accession no. NR074421), M. chelonae (GenBank
accession no. AY457082), and M. abscessus subsp. bolletii
(GenBank accession no. NR043236). The rpoB sequences
showed 99.7 % similarity to those of theM. abscessus subsp.
abscessus type strain, with only a 2-base mismatch (Gen-
Bank accession no. CU458896). The hsp65 sequences were
100 % identical to those of the M. abscessus subsp. absces-
sus type strain (GenBank accession no. CU458896). The
isolate was identified asM. abscessus subsp. abscessus by se-
quencing based method.
Drug susceptibility testing was performed using a
broth microdilution method and M. peregrinum ATCC
700686 was used for quality control according to the
guidelines [25], revealing that the isolate was susceptible
to clarithromycin (minimum inhibitory concentration
[MIC], ≤0.5 μg/mL), even after extended incubation for
14 days (Table 1). The isolate was genotyped for erm(41)
polymorphism and for rrl mutation, which are known as
the main mechanisms of macrolide resistance [26]. The
isolate had a point mutation of C→ T at position 19
(C19→T) in the erm(41) gene, instead of the expected
C28 sequevar of erm(41). It also had no rrl mutation. To
the best of our knowledge, the C19→T mutation of
erm(41) in M. abscessus subsp. abscessus is the first
description.
The patient received oral clarithromycin (1,000 mg/d)
with an initial 4-week hospitalization for intravenous
amikacin and cefoxitin [27, 28]. At day 20 of treatment,
clarithromycin was switched to azithromycin (250 mg/d)
due to gastrointestinal disturbance. After discharge, the
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patient received oral azithromycin for a total duration of
15 months. Her sputum cultures converted to and
remained negative after 2 months of antibiotic treat-
ment. Chest CT at 12 months of treatment revealed im-
provement in consolidations and bronchiolitis (Fig. 1b).
Discussion
It is important to distinguish the three subspecies of
MABC because of their differences in susceptibility to
clarithromycin [29–32]. M. abscessus subsp. abscessus,
M. abscessus subsp. massiliense, and M. abscessus subsp.
bolletii are commonly inducible resistant, susceptible,
and resistant to clarithromycin, respectively [15].
This is the first case of pulmonary disease caused by a
strain of M. abscessus subsp. abscessus showing a clari-
thromycin susceptible phenotype due to the T19 seque-
var of erm(41) gene. According to a previously reported
paper by Nash et al., M. abscessus subsp. abscessus
strains with T28→ C had no inducible resistance to clar-
ithromycin and had low MIC. In the present study, the
M. abscessus subsp. abscessus clinical isolate had a C-to-
T mutation at position 19 (C19→T) leading to an
Arg→ Stop codon change at codon 7 of the erm(41)
gene. This strain was named SMC-Mabs-T19. The
SMC-Mabs-T19 strain revealed low MIC, similar to the
M. abscessus subsp. abscessus strain with a C28 seque-
var. Therefore, maintenance of low clarithromycin MIC
against the SMC-Mabs-T19 strain might have been a
result of the production of non-functional Erm(41). The
entire erm(41) sequence of the susceptible isolate SMC-
Mabs-C19 was unique and differed from that of M.
abscessus subsp. abscessus type strain (GenBank acces-
sion no. CU458896) by only two bases: a C-to-T muta-
tion at position 19 (C19→ T), and a T-to-C mutation at
position 159 (T159→C) (Fig. 2a and b). Of these differ-
ences, T159→ C was also present in the inducible
resistant strains MC719 and UC22 (GenBank accession
nos. EU177504 and CP012044, respectively). Therefore,
the T19 sequevar was the most likely explanation for
the lack of function of erm(41) alleles from the SMC-
Mabs-T19 strain. Until now, erm(41) with a T19 seque-
var has not been reported in GenBank. However, we
found only two M. abscessus subsp. abscessus clinical
isolates harboring erm(41) with C19→G or A point
mutations, and more information regarding drug sus-
ceptibility was not available (GenBank accession nos.
FJ358485 and KP702837, respectively; Fig. 2b).
Conclusions
The erm(41) gene is clinically important, and non-
functional erm alleles may be an important issue for
management of MABC lung disease. The presence of
a non-functional erm(41) allele in M. abscessus
subsp. abscessus isolates may be associated with bet-
ter outcomes.
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review board of the Samsung Medical Center (IRB ap-
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Fig. 1 A 62-year-old female with bronchiectasis and nontuberculous mycobacterial lung disease caused by Mycobacterium abscessus subsp. abscessus.
a Transverse chest computed tomography scan (2.5-mm-section thickness) at the start treatment revealed bilateral bronchiectasis and consolidations
(white arrows) in the right middle lobe and lingular division of the left upper lobe as well as multiple tree-in-bud appearances (black arrow), suggesting
bronchiolitis. b Transverse chest computed tomography scan (2.5-mm-section thickness) at 12 months of antibiotic treatment revealed decreased
consolidation around the bronchiectasis (white arrows) and decreased bronchiolitis (black arrow)
Table 1 Drug susceptibility testing results for antimicrobial
agents against the isolate
Drug MIC (μg/mL) for each category MIC of isolate
(μg/mL)Susceptible Intermediate Resistant
Amikacin ≤16 32 ≥64 8
Cefoxitin ≤16 32–64 ≥128 64
Imipenem ≤4 8–16 ≥32 8
Clarithromycin ≤2 4 ≥8 ≤0.5
Ciprofloxacin ≤1 2 ≥4 >16
Moxifloxacin ≤1 2 ≥4 16
Doxycycline ≤1 2–4 ≥8 >32
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Fig. 2 Analysis of DNA sequences in the erm(41) of Mycobacterium abscessus subsp. abscessus clinical isolate SMC-Mabs-T19. a Phylogenetic position of
isolate SMC-Mabs-T19 and other strains belonging to M. abscessus complex based on entire erm(41) gene sequences. This tree was constructed using the
neighbor-joining method. Percentages indicated at nodes represent the bootstrap levels supported by 1,000 re-sampled datasets. Scale bars indicate
evolutionary distance in base substitutions per site. b Sequence alignment of erm(41) from SMC-Mabs-T19 and other strains belonging to the M. abscessus
complex. Base numbering is from the first base of erm(41). Identical nucleotides are indicated by an asterisk below sequences. Two deletion sites of M.
abscessus subsp. massiliense are indicated by dashes
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